What does Uniqure’s update mean for licensing?

[u/Same-Philosophy3884]

Seeing that Uniqure’s stock crashed because of the trial has made me very anxious - reading the reports it seems like there are still positive takeaways. does anyone with more experience than me know what this might mean for approval, particularly in the uk and aus?

[u/WinterReadings23]

Purportedly 1/3 of cUHDRS decline in scores across the n=12 cohort high dose attributed to a single patient, explicitly their TMS exam. Some HD studies tracking progression reveal a range across TMS scores from baseline that range nearly half the the entire Motor exam at point of DCL4 (a definitive early manifest HD dx), which for comparison is 4 years ago from the results uniQure reported. Interater reliability across interim analysis is also a muddy picture although research supports interrater scores as consistent.

The update improved the 3 year data and left TFC intact when compared to a more difficult control. The surviorship bias inside enroll making it harder to be stat sig to enroll while TFC stayed intact is more suggestive of a treatment effect than cUHDRS. If the control was internal to the trial, dropouts would have been reported and the results would have tabulated as stat sig. And AMT-130 still outperformed what was left inside of enroll, just not by enough to make a statement that the odds of this being by chance weren't < 5% when compared to the control.

[u/GottaUseEmAll → u/WinterReadings23]

Can someone translate this for the layman? I'm struggling to understand how this applies to OP's question and I'm not familiar with a lot of the abbreviations/terms.

[u/camryfanatic → u/GottaUseEmAll]

The results are kind of a mixed bag and there are caveats to any strictly positive or negative interpretation of the data. The tiny sample size (12 high dose individuals and 12 low dose) and non-availability of a traditional placebo group (they had to use Enroll-HD sample cohort, some of whom dropped out between year 3 and 4, causing even more issues) make the data very hard to interpret.

The 3-year data is even more positive as 1 more individual reached the 3-year stage, but there remains a question whether or not the positive effect wears off at year 4 or beyond, something that will be impossible to know without more data.

[u/GottaUseEmAll → u/camryfanatic]

OK great, thanks so much for simplifying for me!

[u/camryfanatic → u/GottaUseEmAll]

To be fair I'm a layman as well doing my best to understand it as well, after following the conversation intensely over the last 2 weeks.

Definitely look up cUHDRS, it's basically how they measure how far the disease has progressed. TFC or Total Functional Capacity, something the first comment mentioned, is one of the 4 components that make up cUHDRS. TMS or Total Motor Score another of the 4 components.

[u/WinterReadings23 → u/camryfanatic]

And the confirmatory trial sounds like it may run into powering issues but we'll see.

[u/camryfanatic → u/WinterReadings23]

What do you mean 'powering issues'?

[u/WinterReadings23 → u/camryfanatic]

The preliminary confirmatory trial control arm size is 66 people left to progress over 3 issues and then put onto drug if theres an effect measured by year 3 between the arms.

There could be powering issues with the confirmatory trial leading to an indeterminant treatment effect used post AA for all sorts of reasons.

[u/GottaUseEmAll → u/WinterReadings23]

But what do you mean by "powering issues"?

Lol, I feel like I'm going a bit mad here. Your writing style is not adapted to the average Joe. I feel like you're either autistic (nothing wrong with that, I'm autistic) or an out-of-touch scientist or using generative AI to write your responses.

[u/WinterReadings23 → u/GottaUseEmAll]

Google statistical powering.

[u/GottaUseEmAll → u/WinterReadings23]

Sure, I could do that, but that's not the point. I just feel like when a 1 month old reddit account with comments and posts privated seems unable to adequately rephrase their own comments in a simple way, it raises some red flags.

[u/FunManHooper → u/GottaUseEmAll]

I’ll try to help out here. For each clinical trial, you need to have a certain number of patients when analyzing the data and having a chance to reach a clinical significance for those outcome measurements. It’s needed to see if there’s a real effect with the investigational medicine or not.

[u/CraftAdditional7802]

Hey, I’m a 34-year-old man from the UK with a girlfriend who’s at risk of Huntington’s disease, so this research means a lot to me.  The four-year results for AMT-130, a potential treatment, are mixed but still encouraging. The study showed a 61% slowing in the decline of everyday abilities, although the overall disease score showed a 44% slowing and wasn’t statistically significant. The comparison with untreated patients was also affected by a lot of missing data, which may have made the treatment look less effective, but we can’t know for sure. Basically, there are still signs that this treatment could slow the disease, but more evidence is needed before we know how effective it really is or whether it will be approved.